Eric Richman

CEO at Gain Therapeutics and 2 other companies
On the record
Represented by:
Bio

Eric I. Richman began his career in venture capital at HealthCare Ventures and most recently was venture partner at Brace Pharma Capital, a life science venture capital firm. He also serves as an advisor to Broad Oak Capital, a life science private equity firm and as a Venture Partner at Allele Capital. Mr. Richman has also previously served as chief executive officer of Tyrogenex and PharmAthene, subsequently acquired by Altimmune.

Recent Quotes
Sign up to view all
  • We identified two STAR lead candidates that have the potential to help Parkinson’s patients with GBA1 gene mutations as well as patients whose GCase protein is misfolded due to aging cellular processes.

    28 July 2021
  • article
    28 July 2021
Employment
Sign up to view all
  • Gain Therapeutics
    CEO
    started Jul 2020
  • InFuse Holdings
    Director & Co-Founder
    started Jun 2019
  • NeuBase Therapeutics
    Director